Table 4.

Median survival time in months (mo) by sex and age with and without bevacizumab on E4599 (N = 850) using age 60 as a cut-point.

	Age		p value-age
	<60 years	≥60 years
Women − Bev	11.0 mo (8.2–14.2) N = 75	13.8 mo (12.4–19.6) N = 105	0.11
Women + Bev	15.5 mo (11.0–21.0) N = 85	12.8 mo (10.8–17.0) N = 122	0.18
Men − Bev	9.3 mo (7.3–10.8) N = 95	8.5 mo (7.1–10.3) N = 158	0.85
Men + Bev	12.4 mo (10.2–15.2) N = 73	11.0 mo (9.3–14.4) N = 137	0.59
p value-sex/treatment	0.0006	<0.0001

Mo, months; Bev, bevacizumab.